November 10, 2025 — Leads & Copy —
Toronto – Venus Concept Inc., a global medical aesthetic technology company, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Venus NOVA™ system.
The Venus NOVA platform is designed for non-invasive treatments for the body, face, and skin. It integrates adaptive electrical muscle stimulation (EMS), proprietary (MP)² technology combining Multi-Polar Radio Frequency (RF) with Pulsed Electromagnetic Fields (PEMF), and advanced VariPulse™ technology.
The company says that this comprehensive solution offers body contouring, muscle conditioning, skin treatments, and wrinkle and cellulite reduction.
Venus NOVA incorporates IoT connectivity through Venus Connect™, a secure, cloud-based application, clinics can access real-time analytics, treatment insights, and automatic system optimization. This is intended to enhance efficiency and profitability.
Key innovations include FlexMAX EMS, which uses a dual-electrode design to deliver adaptive electrical stimulation, activating up to eight muscle groups with up to 100,000 contractions per session. Also included are 4D Body, OctiPolar™, and DiamondPolar™ applicators ergonomically designed for precision, comfort, and versatility across body and facial applications.
The (MP)² technology is a proprietary combination of Multi-Polar RF and PEMF that promotes collagen renewal and improves overall skin appearance. Advanced VariPulse™ uses adjustable suction with positive and negative pressure to enhance RF delivery, improve circulation, and support smoother contours. Automatic Temperature Control (ATC) provides real-time monitoring to maintain optimal temperature for effective treatments.
Rajiv De Silva, Chief Executive Officer of Venus Concept, said that the Venus NOVA launch aligns with the company’s turnaround strategy implemented in 2023 and its Venus AI strategic initiative.
Melissa Kang, Chief Product Officer for Venus Concept, said Venus NOVA is positioned to enhance body transformation journeys, including for those taking GLP-1 medications and experiencing skin laxity, facial volume loss, and body contour irregularities.
Venus NOVA is supported by the Venus Jumpstart Program, a 30-day roadmap providing advanced clinical education, marketing enablement, and strategic implementation. This ensures seamless integration into existing practices and accelerates business success.
Venus NOVA will be available to customers in the United States in December 2025, with global rollouts planned throughout 2026 and beyond.
Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies, reaching over 60 countries and nine direct markets. Venus Concept’s hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners, HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, Masters Special Situations, and Madryn Asset Management, L.P.
Mike Piccinino, CFA
VenusConceptIR@ICRHealthcare.com
Source: Venus Concept
